
Robert A Copeland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3304264/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug–target residence time and its implications for lead optimization. Nature Reviews Drug Discovery, 2006, 5, 730-739.	21.5	1,237
2	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20980-20985.	3.3	608
3	The drug–target residence time model: a 10-year retrospective. Nature Reviews Drug Discovery, 2016, 15, 87-95.	21.5	540
4	Residence Time of Receptorâ [^] 'Ligand Complexes and Its Effect on Biological Function. Biochemistry, 2008, 47, 5481-5492.	1.2	469
5	Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i> -Mutant Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics, 2014, 13, 842-854.	1.9	457
6	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncology, The, 2018, 19, 649-659.	5.1	450
7	Mechanistic considerations in high-throughput screening. Analytical Biochemistry, 2003, 320, 1-12.	1.1	151
8	A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7625-7630.	3.3	112
9	RNA-modifying proteins as anticancer drug targets. Nature Reviews Drug Discovery, 2018, 17, 435-453.	21.5	107
10	Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Analytical Biochemistry, 2011, 416, 206-210.	1.1	82
11	Mechanism of Inhibition of Human KSP by Monastrol:Â Insights from Kinetic Analysis and the Effect of Ionic Strength on KSP Inhibitionâ€. Biochemistry, 2004, 43, 15258-15266.	1.2	52
12	Drug Discovery and Chemical Biology of Cancer Epigenetics. Cell Chemical Biology, 2017, 24, 1120-1147.	2.5	47
13	Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170080.	1.8	34
14	Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2. ACS Chemical Biology, 2014, 9, 2459-2464.	1.6	29
15	Evolution of the drug-target residence time model. Expert Opinion on Drug Discovery, 2021, 16, 1441-1451.	2.5	25
16	The Elements of Translational Chemical Biology. Cell Chemical Biology, 2018, 25, 128-134.	2.5	16
17	A method for determining intracellular concentrations of enzyme substrates from a combination of competitive inhibition and mutagenesis studies. Analytical Biochemistry, 2005, 337, 351-353.	1.1	2
18	Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. Biochemistry, 2021, 60, 2275-2284.	1.2	2

#	Article	IF	CITATIONS
19	Special Issue on Epigenetics: Targeting Chromatin- and RNA- Modifications. ACS Medicinal Chemistry Letters, 2020, 11, 2051-2052.	1.3	Ο
20	A Second p53 Binding Site in the Central Domain of Mdm2 Is Essential for p53 Ubiquitination. FASEB Journal, 2007, 21, A273.	0.2	0